Gene expression profiling of gliomas strongly predicts survival

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6503-6510

  Freije, William A ^a   Castro Vargas, F Edmundo ^a   Fang, Zixing ^a   Horvath, Steve ^a   Cloughesy, Timothy ^a   Liau, Linda M ^a   Mischel, Paul S ^a   Nelson, Stanley F ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGONUCLEOTIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER SURVIVAL; DIAGNOSTIC VALUE; DNA MICROARRAY; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC HETEROGENEITY; GLIOMA; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GLIOMA; HUMANS; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE;

EID: 4644313275     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-0452     Document Type: Article

References (68)

1. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer 2000;88:2887.
2. Louis DN, Holland EC, Cairncross JG. Glioma classification: a molecular reappraisal. Am J Pathol 2001;159:779-86.
3. Prayson RA, Agamanolis DP, Cohen ML, et al. Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading. J Neurol Sci 2000;175:33-9.
4. Coons SW, Johnson PC, Scheithauer BW, Yates AJ, Pearl DK. Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas. Cancer 1997;79:1381-93.
5. Burger PC. What is an oligodendroglioma? Brain Pathol 2002;12:257-9.
6. Mischel PS, Nelson SF, Cloughesy TF. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther 2003;2:242-7.
7. Betensky RA, Louis DN, Cairncross JG. Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol 2002;20:2495-9.
8. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer 2003;97:2381-6.
9. Mischel PS, Shai R, Shi T, et al. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene 2003;22:2361-73.
10. Tortosa A, Vinolas N, Villa S, et al. Prognostic implication of clinical, radiologic, and pathologic features in patients with anaplastic gliomas. Cancer 2003;97:1063-71.
11. Reavey-Cantwell JF, Haroun RI, Zahurak M, et al. The prognostic value of tumor markers in patients with glioblastoma multiforme: analysis of 32 patients and review of the literature. J Neurooncol 2001;55:195-204.
12. Bouvier-Labit C, Chinot O, Ochi C, et al. Prognostic significance of Ki67, p53 and epidermal growth factor receptor immunostaining in human glioblastomas. Neuropathol Appl Neurobiol 1998;24:381-8.
13. Stark AM, Hugo HH, Witzel P, Mihajlovic Z, Mehdorn HM. Age-related expression of p53, Mdm2, EGFR and Msh2 in glioblastoma multiforme. Zentralbl Neurochir 2003;64:30-6.
14. Li J, Yen C, Liaw D, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997;275:1943-7.
15. Kim S, Dougherty ER, Shmulevich L, et al. Identification of combination gene sets for glioma classification. Mol Cancer Ther 2002;1:1229-36.
16. Ljubimova JY, Lakhter AJ, Loksh A, et al. Overexpression of alpha4 chain-containing laminins in human glial tumors identified by gene microarray analysis. Cancer Res 2001;61:5601-10.
17. Nutt CL, Mani DR, Betensky RA, et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res 2003;63:1602-7.
18. Rickman DS, Bobek MP, Misek DE, et al. Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide microarray analysis. Cancer Res 2001;61:6885-91.
19. Sallinen SL, Sallinen PK, Haapasalo HK, et al. Identification of differentially expressed genes in human gliomas by DNA microarray and tissue chip techniques. Cancer Res 2000;60:6617-22.
20. Shai R, Shi T, Kremen TJ, et al. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene 2003;22:4918-23.
21. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res 2002;62:4364-8.
22. Li C, Wong WH. Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci USA 2001;98:31-6.
23. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Cox DR, Oakes D. Analysis of survival data. London: Chapman and Hall; 1990.
25. de Jong S. SIMPLS: an alternative approach to partial least squaresregression. Chemometrics and Intelligent Laboratory Systems 1993;18:251-63.
26. Therneau TM, Grambsch PM, Fleming TR. Martingale-based residuals and survival models. Biometrika 1990;77:147-60.
27. Kaufman L, Rousseeuw PJ. Finding groups in data, an introduction to cluster analysis. Brussels: John Wiley & Sons; 1990.
28. Cox T F, Cox, MA. Multidimensional scaling. London: Chapman and Hall; 1994.
29. Burger PC, Vogel FS, Green SB, Strike TA. Glioblastoma multiforme and anaplastic astrocytoma. Pathologic criteria and prognostic implications. Cancer 1985;56:1106-11.
30. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 2003;4:R70.
31. Zhang X, Wu J, Li X, et al. Effects of recombinant human bone morphogenic protein-2 and hyaluronic acid on invasion of brain glioma in vivo. Zhonghua Yi Xue Za Zhi 2002;82:90-3.
32. Tatenhorst L, Senner V, Puttmann S, Paulus W. Regulators of G-protein signaling 3 and 4 (RGS3, RGS4) are associated with glioma cell motility. J Neuropathol Exp Neurol 2004;63:210-22.
33. Fischer U, Muller HW, Sattler HP, et al. Amplification of the MET gene in glioma. Genes Chromosomes Cancer 1995;12:63-5.
34. Holden JA, Townsend JJ. DNA topoisomerase II-alpha as a proliferation marker in astrocytic neoplasms of the central nervous system: correlation with MIB1 expression and patient survival. Mod Pathol 1999;12:1094-100.
35. Sandberg AC, Engberg C, Lake M, von Holst H, Sara VR. The expression of insulin-like growth factor I and insulin-like growth factor II genes in the human fetal and adult brain and in glioma. Neurosci Lett 1988;93:114-9.
36. Fiano V, Ghimenti C, Schiffer D. Expression of cyclins, cyclin-dependent kinases and cyclin-dependent kinase inhibitors in oligodendrogliomas in humans. Neurosci Lett 2003;347:111-5.
37. van den Boom J, Wolter M, Kuick R, et al. Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based microarray analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol 2003;163:1033-43.
38. Kawataki T, Naganuma H, Sasaki A, et al. Correlation of thrombospondin-1 and transforming growth factor-beta expression with malignancy of glioma. Neuropathology 2000;20:161-9.
39. Plate KH, Breier G, Weich HA, Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-8.
40. Belot N, Pochet R, Heizmann CW, Kiss R, Decaestecker C. Extracellular S100A4 stimulates the migration rate of astrocytic tumor cells by modifying the organization of their actin cytoskeleton. Biochim Biophys Acta 2002;1600:74-83.
41. Bouterfa H, Darlapp AR, Klein E, et al. Expression of different extracellular matrix components in human brain tumor and melanoma cells in respect to variant culture conditions. J Neurooncol 1999;44:23-33.
42. von Deimling A, von Ammon K, Schoenfeld D, et al. Subsets of glioblastoma multiforme defined by molecular genetic analysis. Brain Pathol 1993;3:19-26.
43. Dai C, Celestino JC, Okada Y, et al. PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 2001;15:1913-25.
44. Holland EC, Li Y, Celestino J, et al. Astrocytes give rise to oligodendrogliomas and astrocytomas after gene transfer of polyoma virus middle T antigen in vivo. Am J Pathol 2000;157:1031-7.
45. Holland EC. Progenitor cells and glioma formation. Curr Opin Neurol 2001;14:683-8.
46. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-9.
47. Gracia E, Fischer U, elKahloun A, et al. Isolation of genes amplified in human cancers by microdissection mediated cDNA capture. Hum Mol Genet 1996;5:595-600.
48. Reifenberger G, Reifenberger J, Ichimura K, Meltzer PS, Collins VP. Amplification of multiple genes from chromosomal region 12q13-14 in human malignant gliomas: preliminary mapping of the amplicons shows preferential involvement of CDK4, SAS, and MDM2. Cancer Res 1994;54:4299-303.
49. Arheden K, Ronne M, Mandahl N, et al. In situ hybridization localizes the human putative oncogene GLI to chromosome subbands 12q13.3-14.1. Hum Genet 1989;82:1-2.
50. Ichimura K, Schmidt EE, Goike HM, Collins VP. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996;13:1065-72.
51. Collins VP. Amplified genes in human gliomas. Semin Cancer Biol 1993;4:27-32.
52. Buschges R, Weber RG, Actor B, et al. Amplification and expression of cyclin D genes (CCND1, CCND2 and CCND3) in human malignant gliomas. Brain Pathol 1999;9:435-42; discussion 2-3.
53. Moriyama T, Kataoka H, Seguchi K, Tsubouchi H, Koono M. Effects of hepatocyte growth factor (HGF) on human glioma cells in vitro: HGF acts as a motility factor in glioma cells. Int J Cancer 1996;66:678-85.
54. Riemenschneider MJ, Buschges R, Wolter M, et al. Amplification and overexpression of the MDM4 (MDMX) gene from 1q32 in a subset of malignant gliomas without TP53 mutation or MDM2 amplification. Cancer Res 1999;59:6091-6.
55. Steck PA, Saya H. Pathways of oncogenesis in primary brain tumors. Curr Opin Oncol 1991;3:476-84.
56. Fitzgibbons PL, Turner RR, Appley AJ, et al. Flow cytometric DNA and nuclear antigen content in astrocytic neoplasms. Am J Clin Pathol 1988;89:640-4.
57. Chakravarti A, Delaney MA, Noll E, et al. Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 2001;7:2387-95.
58. Katayam M, Yoshida K, Ishimori H, et al. Patched and smoothened mRNA expression in human astrocytic tumors inversely correlates with histological malignancy. J Neurooncol 2002;59:107-15.
59. Haas-Kogan D, Shalev N, Wong M, et al. Protein kinase B (PKB/Akt) activity is elevated in glioblastoma cells due to mutation of the tumor suppressor PTEN/MMAC. Curr Biol 1998;8:1195-8.
60. Mapstone TB. Expression of platelet-derived growth factor and transforming growth factor and their correlation with cellular morphology in glial tumors. J Neurosurg 1991;75:447-51.
61. Unterman TG, Glick RP, Waites GT, Bell SC. Production of insulin-like growth factor-binding proteins by human central nervous system tumors. Cancer Res 1991;51:3030-6.
62. Westermark B, Magnusson A, Heldin CH. Effect of epidermal growth factor on membrane motility and cell locomotion in cultures of human clonal glioma cells. J Neurosci Res 1982;8:491-507.
63. Dahlstrand J, Collins VP, Lendahl U. Expression of the class VI intermediate filament nestin in human central nervous system tumors. Cancer Res 1992;52:5334-41.
64. Dittmann L, Axelsen NH, Norgaard-Pedersen B, Bock E. Antigens in human glioblastomas and meningiomas: Search for tumour and onco-foetal antigens. Estimation of S-100 and GFA protein. Br J Cancer 1977;35:135-41.
65. Araki K, Nozaki K, Ueba T, Tatsuka M, Hashimoto N. High expression of Aurora-B/Aurora and Ip11-like midbody-associated protein (AIM-1) in astrocytomas. J Neurooncol 2004;67:53-64.
66. Wharton SB, Chan KK, Anderson JR, Stoeber K, Williams GH. Replicative Mcm2 protein as a novel proliferation marker in oligodendrogliomas and its relationship to Ki67 labelling index, histological grade and prognosis. Neuropathol Appl Neurobiol 2001;27:305-13.
67. Halfter H, Kremerskothen J, Weber J, et al. Growth inhibition of newly established human glioma cell lines by leukemia inhibitory factor. J Neurooncol 1998;39:1-18.
68. Rao JS, Steck PA, Mohanam S, et al. Elevated levels of M(r) 92,000 type IV collagenase in human brain tumors. Cancer Res 1993;53:2208-11.